27164711|t|Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
27164711|a|OBJECTIVE: We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity. METHODS: In this cross-sectional multicenter study (a subset of the prospective Swedish BioFINDER study), we included 4 groups, representing the different stages of predementia AD: (1) cognitively healthy elderly with normal CSF beta-amyloid 42 (Abeta42), (2) cognitively healthy elderly with abnormal CSF Abeta42, (3) patients with subjective cognitive decline and abnormal CSF Abeta42, (4) patients with mild cognitive decline and abnormal CSF Abeta42 (Ntotal = 352). Spectroscopic markers measured in the posterior cingulate/precuneus were considered alongside known disease biomarkers: CSF Abeta42, phosphorylated tau, total tau, [(18)F]-flutemetamol PET, f-MRI, and the genetic risk factor APOE. RESULTS: Amyloid-positive cognitively healthy participants showed a significant increase in mI/creatine and mI/NAA levels compared to amyloid-negative healthy elderly (p < 0.05). In amyloid-positive healthy elderly, mI/creatine and mI/NAA correlated with cortical retention of [(18)F] flutemetamol tracer ([Formula: see text] = 0.44, p = 0.02 and [Formula: see text] = 0.51, p = 0.01, respectively). Healthy elderly APOE epsilon4 carriers with normal CSF Abeta42 levels had significantly higher mI/creatine levels (p < 0.001) than epsilon4 noncarriers. Finally, elevated mI/creatine was associated with decreased functional connectivity within the default mode network (rpearson = -0.16, p = 0.02), independently of amyloid pathology. CONCLUSIONS: mI levels are elevated already at asymptomatic stages of AD. Moreover, mI/creatine concentrations were increased in healthy APOE epsilon4 carriers with normal CSF Abeta42 levels, suggesting that mI levels may reveal regional brain consequences of APOE epsilon4 before detectable amyloid pathology.
27164711	0	12	Myo-inositol	Chemical	MESH:D007294
27164711	29	46	amyloid pathology	Disease	MESH:C000718787
27164711	61	65	APOE	Gene	348
27164711	78	95	Alzheimer disease	Disease	MESH:D000544
27164711	201	213	myo-inositol	Chemical	MESH:D007294
27164711	215	217	mI	Chemical	MESH:D007294
27164711	220	237	N-acetylaspartate	Chemical	MESH:C000179
27164711	239	242	NAA	Chemical	MESH:C000179
27164711	249	256	choline	Chemical	MESH:D002794
27164711	297	314	Alzheimer disease	Disease	MESH:D000544
27164711	316	318	AD	Disease	MESH:D000544
27164711	358	361	tau	Gene	4137
27164711	579	581	AD	Disease	MESH:D000544
27164711	648	655	Abeta42	Gene	351
27164711	708	715	Abeta42	Gene	351
27164711	721	729	patients	Species	9606
27164711	746	763	cognitive decline	Disease	MESH:D003072
27164711	781	788	Abeta42	Gene	351
27164711	794	802	patients	Species	9606
27164711	813	830	cognitive decline	Disease	MESH:D003072
27164711	848	855	Abeta42	Gene	351
27164711	996	1003	Abeta42	Gene	351
27164711	1020	1023	tau	Gene	4137
27164711	1031	1034	tau	Gene	4137
27164711	1036	1056	[(18)F]-flutemetamol	Chemical	MESH:C581552
27164711	1097	1101	APOE	Gene	348
27164711	1195	1197	mI	Chemical	MESH:D007294
27164711	1198	1206	creatine	Chemical	MESH:D003401
27164711	1211	1213	mI	Chemical	MESH:D007294
27164711	1214	1217	NAA	Chemical	MESH:C000179
27164711	1285	1292	amyloid	Disease	MESH:C000718787
27164711	1319	1321	mI	Chemical	MESH:D007294
27164711	1322	1330	creatine	Chemical	MESH:D003401
27164711	1335	1337	mI	Chemical	MESH:D007294
27164711	1338	1341	NAA	Chemical	MESH:C000179
27164711	1380	1387	[(18)F]	Chemical	MESH:C000615276
27164711	1388	1400	flutemetamol	Chemical	MESH:C581552
27164711	1519	1523	APOE	Gene	348
27164711	1558	1565	Abeta42	Gene	351
27164711	1598	1600	mI	Chemical	MESH:D007294
27164711	1601	1609	creatine	Chemical	MESH:D003401
27164711	1674	1676	mI	Chemical	MESH:D007294
27164711	1677	1685	creatine	Chemical	MESH:D003401
27164711	1819	1836	amyloid pathology	Disease	MESH:C000718787
27164711	1851	1853	mI	Chemical	MESH:D007294
27164711	1908	1910	AD	Disease	MESH:D000544
27164711	1922	1924	mI	Chemical	MESH:D007294
27164711	1925	1933	creatine	Chemical	MESH:D003401
27164711	1975	1979	APOE	Gene	348
27164711	2014	2021	Abeta42	Gene	351
27164711	2046	2048	mI	Chemical	MESH:D007294
27164711	2098	2102	APOE	Gene	348
27164711	2130	2147	amyloid pathology	Disease	MESH:C000718787
27164711	Association	MESH:C000615276	MESH:D003401
27164711	Association	MESH:D007294	MESH:D000544
27164711	Association	MESH:D007294	MESH:C000718787
27164711	Association	MESH:C581552	MESH:D003401
27164711	Association	MESH:C000179	MESH:C581552
27164711	Association	MESH:D000544	348
27164711	Association	MESH:D003401	MESH:D007294
27164711	Association	MESH:C581552	MESH:D007294

